Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Myelofibrosis with Myeloid Metaplasia
NCT00015821Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2000
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in primary myelofibrosis (PMF), sponsored by National Cancer Institute. Primary endpoint: Confirmed Response up to 5 years. Started May 2000; status: completed.
02
Drugs
thalidomide
03
Conditions
primary myelofibrosis (PMF)
Beyond the preview
Go deeper on NCT00015821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00015821.